A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Terminated · Phase 1 · NCT05578092
Conditions: Solid Tumor, Advanced Solid Tumor, Non Small Cell Lung Cancer, Colo-rectal Cancer
At a glance
- Research payments reported, 2025
- $1.8M
- U.S. investigators named
- 17
- Sites paid
- 14
- Planned or actual enrollment
- 64
About the trial
- Sponsor
- Mirati Therapeutics Inc.
- Tested
- MRTX0902 (drug), MRTX849 (drug)
- Dates
- Started 2022-12-02; completion 2026-02-03
- Results posted
- Not yet
This is a Phase 1, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways.
From ClinicalTrials.gov, last updated 2026-02-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $1.8M in research payments for this study in 2025 (18 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Erminia Massarelli, MD Medical Oncology · Duarte, CA
- Jason Henry, M.D Internal Medicine · Denver, CO
- So Yeon Kim, MD Medical Oncology · North Haven, CT
- Jamal G. Misleh, MD Hematology & Oncology · Newark, DE
- Cesar A. Perez Batista, M.D. Medical Oncology · Orlando, FL
- Elena G. Chiorean, M.D. Medical Oncology · Chicago, IL
- Nilofer S. Azad, MD Medical Oncology · Baltimore, MD
- Konstantinos Leventakos, M.D. Medical Oncology · Rochester, MN
- Martin E. Gutierrez, MD Medical Oncology · Hackensack, NJ
- Davendra P. Sohal, MD, MPH Hematology & Oncology · Cincinnati, OH
- Shivaani Kummar Medical Oncology · Portland, OR
- Liza C. Villaruz, M.D. Internal Medicine · Pittsburgh, PA
- Marcia R. Cruz-correa, MD Gastroenterology · Rio Piedras, PR
- Melissa L. Johnson, MD Medical Oncology · Nashville, TN
- David S. Hong, M.D. Medical Oncology · Houston, TX
- Andrew S. Paulson, MD Medical Oncology · Dallas, TX
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute, Llc $405,220
- UC Health, University of Cincinnati $358,848
- Pan American Center for Oncology Trials Llc $191,447
- Mayo Clinic Sports Medicine $145,884
- University of Washington Medical Ctr, WA $142,926
- Yale University $116,964
- Ut MD Anderson Cancer Center $109,403
- Next Oncology $105,793
- The Johns Hopkins University $78,748
- The Johns Hopkins Medicine Irbs $53,980
- University of Pittsburgh Cancer Institute Cancer Services $37,565
- Ohsu Hospital and Clinics, OR $36,789
- Hackensack University Medical Center, NJ $29,118
- University of Texas Health Science Center at Tyler, TX $19,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.